ONCOHIGH SIGNALMANAGEMENT10-K

ONCO executed a 1:85 reverse stock split and is pursuing a major business transformation through the Realbotix Transaction, moving away from its previous pharmaceutical focus.

The company appears to be pivoting from its core oncology business model, as evidenced by the shift from discussing pharmaceutical acquisitions (ENTADFI, Proteomedix) to robotics/AI ventures (Realbotix). The extreme reverse stock split ratio of 1:85 suggests severe share price distress and potential delisting concerns. This represents a fundamental change in business direction rather than organic growth in existing operations.

Comparing 2026-03-13 vs 2025-06-02View on EDGAR →
FINANCIAL ANALYSIS

ONCO's financial performance deteriorated substantially across revenue and profitability metrics, though losses narrowed meaningfully due to dramatic cost reductions. R&D spending collapsed by over 90%, revenue declined significantly, and gross profit dropped 40%, while SG&A expenses were cut by 37%. The company reduced total liabilities by roughly half while maintaining most of its asset base, suggesting active debt management during this transition period.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
-92.1%
$1.9M→$154K

R&D spending cut 92.1% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+76.1%
-$58.7M→-$14.0M

Net income grew 76.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+68.4%
-$56.5M→-$17.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Revenue
P&L
-67.7%
$2.5M→$815K

Revenue declined 67.7% — significant demand weakness or market share loss warrants investigation.

Total Liabilities
Balance Sheet
-50.7%
$18.6M→$9.2M

Liabilities reduced 50.7% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-50%
$18.3M→$9.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
-40%
$1.1M→$633K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

SG&A Expense
P&L
-37.3%
$11.2M→$7.0M

SG&A reduced 37.3% — improved cost efficiency or headcount reduction improving operating margins.

Total Assets
Balance Sheet
-11.5%
$28.2M→$24.9M

Total assets contracted 11.5% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-06-02
ADDED
As of March 11, 2026, the registrant had 3,584,245 shares of common stock, $0.00001 par value per share, outstanding.
EXPLANATORY NOTE On June 13, 2025, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-eighty-five (1:85).
All issued and outstanding common stock, common stock warrants, and share-based awards exercise prices and per share data have been adjusted in these consolidated financial statements, on a retrospective basis, to reflect the reverse stock split for all periods presented.
our ability to consummate the transaction on a timely basis as contemplated by the Share Exchange Agreement with Realbotix, LLC ( Realbotix and the Share Exchange Agreement and the transactions contemplated therein, the Realbotix Transaction ) and the anticipated benefits of the Realbotix Transaction.
These risks include, but are not limited to, the following: We could fail to complete the Realbotix Transaction, or the Realbotix Transaction may be completed on different terms.
+7 more — sign up free →
REMOVED
As of May 30, 2025, the registrant had 44,358,422 shares of common stock, $0.00001 par value per share, outstanding.
EXPLANATORY NOTE On September 24, 2024, the Company effected a Reverse Stock Split of all shares of its issued and outstanding Common Stock at a ratio of one-for-forty (1:40).
All issued and outstanding common stock, common stock warrants, and share-based awards exercise prices and per share data in this report and the consolidated financial statements have been adjusted, on a retrospective basis, to reflect the reverse stock split for all periods presented.
These risks include, but are not limited to, the following: Company shareholders may not realize a benefit from the ENTADFI or Proteomedix ( Proteomedix ) acquisitions commensurate with the ownership dilution they have experienced in connection with the transactions.
We may consider strategic alternatives in order to maximize stockholder value, including financing, strategic alliances, licensing arrangements, acquisitions or the possible sale of our business.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →